| 标题 |
Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial |
| 网址 | |
| DOI | |
| 其它 |
期刊:Lancet Oncology 作者:Joseph Gligorov; Dinesh Doval; José Bines; Emilio Alba; Paulo Cortes; et al 出版日期:2014-09-28 |
| 求助人 | |
| 下载 | 求助已完成,仅限求助人下载。 |
PDF的下载单位、IP信息已删除
(2025-6-4)